Pills of different shapes a colours

Collection call for papers: Cancer therapy toxicity

Guest edited by Dr Raymond Mak, Dr Miranda Fidler-Benaoudia, and Dr Lova Sun.


  • Petri dish with cultures of different colours

    We welcome submissions of primary research that address the problem of antimicrobial resistance (AMR) and suboptimal antimicrobial use in human medicine. Given the need for a multi-modal approach to this problem, we encourage submissions focusing on diagnostics, novel agent discovery, optimisation of current antimicrobial agents, behavioural interventions, and wider policy approaches to AMR.

    Open for submissions
  • Silhouette of children and adolescents against the sunset from Adobe Stock by Tutye

    In this joint collection, Communications Medicine and Nature Communications are inviting submissions of primary research that aims to understand and improve child and adolescent development and health.

    Open for submissions
  • Heart with two lines in red and blue

    We welcome submissions of primary research on prevention, diagnosis, monitoring and management of cardiac arrhythmias, including both non-invasive and invasive trans-catheter management, as well as the role digital technologies are starting play in the field.

    Open for submissions
  • Metrics

    Communications Medicine is a recently launched fully open access journal already indexed in DOAJ, Google Scholar, and PubMed Central. It takes 7 days from submission to the first editorial decision (median).


    • HIV remains a major global health issue, with the burden of the epidemic disproportionately falling on low- and middle-income countries. Progress in HIV prevention, most notably pre-exposure prophylaxis (PrEP), has been slow to reach those most in need.

      • John Alechenu Idoko
      • Beatriz Grinsztejn
      • Nittaya Phanuphak
      Viewpoint Open Access
    • Koh, Papanikolaou et al. discuss the application of artificial intelligence in cancer imaging. The authors highlight opportunities for exploiting machine learning algorithms in this field, and outline barriers in their implementation and how these might be addressed.

      • Dow-Mu Koh
      • Nickolas Papanikolaou
      • Fred Prior
      Review Article Open Access
    • Traditionally, there has been a reluctance to involve pregnant people in clinical trials due to complex ethical issues surrounding the risk to unborn babies. However it is crucial that new interventions are safe and effective for all patients and ensuring this can be difficult to achieve in the absence of clinical trials.

      • Catriona Waitt
      • Denise Astill
      • Janine A. Clayton
      Viewpoint Open Access
    • Calder, Tong et al. discuss how the rapid development of COVID-19 vaccines benefited from HIV/AIDS research. They highlight lessons learned from the COVID-19 vaccine development experience that could accelerate and re-energize the development of a safe and efficacious HIV vaccine.

      • Thomas Calder
      • Tina Tong
      • M. Patricia D’Souza
      Perspective Open Access
    • Clinical trials are required to ensure new treatments are safe and effective for patients. The involvement of participants in the planning and execution of clinical trials is critical not only to their success but also so that the participating communities can benefit from them.

      • Jan Geißler
      • Emily Isham
      • Cheryl Lubbert
      Viewpoint Open Access
  • Today is Global Recycling Day. All medical practices and disciplines face sustainability issues and there is a huge focus in the UK on minimising the environmental effects of medicine. Here we speak to Dr Daniel Lake about ‘Project Greener Anaesthesia’, which aims to do just that for Anaesthetics.

    Q&A Open Access
  • Professor Bobby Gaspar is a distinguished physician-scientist who is a thought leader in translating basic research from bench-to-bedside and strategic work that facilitated bringing life-saving therapies to patients with rare diseases. He has over 30 years of experience in pediatric medicine working in the NHS and the biotechnology sector, and is the founding member of Orchard Therapeutics, where he serves as Chief Executive Officer. In this Q&A, Professor Gaspar provides insight into the regulatory approval and policy considerations for bringing novel therapies for rare diseases from discovery through to clinical application.

    Q&A Open Access
  • Annemieke Aartsma-Rus is a Professor of Translational Genetics at the Leiden University Medical Center. She was one of the pioneers of antisense oligonucleotide (ASO)-mediated exon skipping therapy for Duchenne muscular dystrophy (DMD). Her work focuses on the personalized approach to delivering exon skipping therapy for patients with rare genetic diseases within the setting of the Dutch Center for RNA Therapeutics, which she co-founded in 2020 and is on the Board of Directors. Currently, four exon skipping drugs have been approved by the US Food and Drug Administration for DMD, three of which are based on the IP generated by Aartsma-Rus’ institute. She is also involved in patient education in collaboration with the Duchenne Patient Academy and the European Organisation for Rare Diseases (Eurordis). In this Q&A, we ask Prof. Aartsma-Rus a series of questions on the latest developments in therapies for rare diseases and how best to overcome some of the existing challenges with this endeavour.

    Q&A Open Access
  • Megan O’Boyle is the parent of a 22-year-old daughter with a rare neurodevelopmental disease. She is currently the Patient Engagement Lead of the RARE-X Data Collection Program at Global Genes, a collaborative platform for global data sharing and analysis created to accelerate treatments for rare diseases. In this Q&A, we ask Megan a series of questions on patient engagement and involvement in rare disease research.

    Q&A Open Access
  • Dr. Stephen Kingsmore is President/CEO of Rady Children’s Hospital. His career as a physician-scientist has covered the implementation of genomic medicine approaches for rare genetic disorders. This has furthered the field of genomic medicine, in which genomic information about an individual is used as part of their clinical care to facilitate diagnosis or improve treatment. In this Q&A, we ask Dr. Kingsmore a series of questions about the challenges in diagnosing rare diseases and how diagnosis could be improved in the future.

    Q&A Open Access
  • Schattenberg et al. outline discussions from a recent workshop on NAFLD care and advocate for a multidisciplinary approach to managing this complex and multifactorial disease. The authors highlight gaps in current models of care and make recommendations on optimising a multistakeholder approach in steatotic liver diseases.

    • Jörn M. Schattenberg
    • Alina M. Allen
    • Jeffrey V. Lazarus
    Comment Open Access
world map with digits on top

Geospatial analysis for improved understanding of health inequalities

This collection welcomes submissions that help in understanding heterogeneity in health outcomes in space and time to and support decision- and policy-making to reduce health inequalities, with a particular interest in submissions focused on LMICs.
Open for submissions